Yervoy 50mg/10ml (Ipilimumab Vials) 50mg/10ml

Ipilimumab 50mg/10ml (Yervoy) is an injectable immunotherapy used to treat certain cancers. This 10ml vial contains 50mg of ipilimumab, a monoclonal antibody. Store between 2-8°C and protect from light. Consult a healthcare provider for suitability.

Strength

50mg/10ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Bristol- Myers Squibb

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ipilimumab 50mg/10ml is primarily used in immunotherapy to help the immune system recognize and attack cancer cells. It is indicated for melanoma and may be used in combination with other cancer treatments. This medication is administered under medical supervision.

Side Effects

As an immunotherapy, ipilimumab works by blocking a protein called CTLA-4, which helps immune cells become more active against cancer. Patients may experience immune-related side effects as the body’s immune response is enhanced. Common effects include fatigue, skin reactions, and gastrointestinal changes.

Precautions & Warnings

Ipilimumab should be handled and administered by healthcare professionals. Store vials refrigerated between 2-8°C and protect from light. Do not freeze or shake vigorously. Patients should report any signs of immune-related reactions, such as rash or diarrhea, to their doctor immediately.

Avoid Interactions

Ipilimumab may interact with other medications that affect the immune system, such as corticosteroids or immunosuppressants. Combining it with certain chemotherapy drugs or targeted therapies should be done under close medical supervision. Alcohol use should be discussed with a healthcare provider.

References

Frequently Asked Questions

Ipilimumab is used in immunotherapy to treat certain cancers, including melanoma, by helping the immune system target cancer cells.

This medication is given as an intravenous infusion by a healthcare professional. The exact dosing and schedule depend on the treatment plan.

Common effects may include fatigue, skin reactions, diarrhea, and nausea. Serious immune-related reactions can occur and should be reported to a doctor.

Ipilimumab is a prescription medication and should only be obtained through licensed pharmacies or healthcare providers.

Store vials refrigerated between 2-8°C and protect from light. Do not freeze or shake the vial.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.